## THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

**If you have sold or transferred** all your shares in **Bamboos Health Care Holdings Limited**, you should at once hand or forward this circular and the accompanying form of proxy to the purchaser(s) or the transferee(s) or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or the transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this circular.

# BAMBOOS HEALTH CARE HOLDINGS LIMITED
# 百本醫護控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2293)**

## PROPOSALS FOR
## (1) GENERAL MANDATES TO ISSUE AND BUY-BACK SHARES;
## (2) RE-ELECTION OF RETIRING DIRECTORS;
## (3) RE-APPOINTMENT OF AUDITOR;
## (4) DECLARATION OF A FINAL DIVIDEND;
## AND
## (5) NOTICE OF THE ANNUAL GENERAL MEETING

A notice convening the Annual General Meeting (as defined below) to be held at Unit 801, 8/F, Good Hope Building, No. 612–618 Nathan Road, Mong Kok, Kowloon, Hong Kong on Friday, 28 November 2025 at 11:00 a.m. is set out on pages AGM-1 to AGM-6 of this circular.

Whether you are able to attend the Annual General Meeting or not, you are requested to complete the enclosed proxy form in accordance with the instructions as indicated on it and return the completed proxy form to the Hong Kong branch share registrar and transfer office of the Company, Union Registrars Limited, at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong as soon as practicable and in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude you from attending and voting in person at the Annual General Meeting or any adjournment thereof (as the case may be) should you so desire.

24 October 2025

# CONTENTS


*Page*

**Definitions** . . . . . 1

**Letter from the Board** . . . . . 4

**Appendix I — Explanatory Statement for the Buy-back Mandate** . . . . . I-1

**Appendix II — Details of the Retiring Directors Proposed to be Re-elected** . . . . . II-1

**Notice of the Annual General Meeting** . . . . . AGM-1

*In this circular, unless the context otherwise requires, the following expressions have the following meanings:*

| | |
|---|---|
| "AGM Notice" | the notice convening the Annual General Meeting set out on pages AGM-1 to AGM-6 of this circular |
| "Annual General Meeting" | the annual general meeting of the Company to be held at Unit 801, 8/F, Good Hope Building, No. 612–618 Nathan Road, Mong Kok, Kowloon, Hong Kong on Friday, 28 November 2025 at 11:00 a.m. or any adjournment thereof (as the case may be) |
| "Articles of Association" | the articles of association of the Company as amended from time to time |
| "Audit Committee" | the audit committee of the Company |
| "Board" | the board of Directors |
| "Branch Share Registrar" | the branch share registrar and transfer office of the Company in Hong Kong, Union Registrars Limited at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong |
| "Buy-back Mandate" | a general and unconditional mandate proposed to be granted to the Directors to enable them to buy-back Shares, the aggregate number of which shall not exceed 10% of the aggregate number of the issued Shares as at the date of passing the relevant resolution, for such period until the conclusion of the next annual general meeting of the Company or such earlier period, at the Annual General Meeting |
| "BVI" | the British Virgin Islands |
| "CCASS" | the Central Clearing and Settlement System established and operated by HKSCC |
| "close associate(s)" | has the meaning as ascribed to it under the Listing Rules |
| "Companies Act" | Companies Act (as revised) of the Cayman Islands, as amended, supplemented or otherwise modified from time to time |

| | |
|---|---|
| "Company" | Bamboos Health Care Holdings Limited (百本醫護控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed and traded on the Main Board of the Stock Exchange (stock code: 2293) |
| "controlling shareholder(s)" | has the meaning as ascribed to it under the Listing Rules |
| "core connected person(s)" | has the meaning as ascribed to it under the Listing Rules |
| "Director(s)" | the director(s) of the Company |
| "Extension Mandate" | a general and unconditional mandate proposed to be granted to the Directors to the effect that any Shares bought back under the Buy-back Mandate will be added to the total number of Shares which may be allotted, issued and dealt with under the Issue Mandate |
| "Gold Empress" | Gold Empress Limited, a company incorporated in the BVI with limited liability, which is solely and beneficially owned by Ms. Hai as at the Latest Practicable Date |
| "Group" | the Company and its subsidiaries |
| "HK$" | Hong Kong dollars, the lawful currency of Hong Kong |
| "HKSCC" | Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited |
| "Hong Kong" | Hong Kong Special Administrative Region of the People's Republic of China |
| "Issue Mandate" | a general and unconditional mandate proposed to be granted to the Directors to exercise the power of the Company to allot, issue and deal with (including but not limited to the resale of treasury shares) additional Shares up to a maximum of 20% of the aggregate number of the issued Shares as at the date of passing of the relevant resolution, for such period until the conclusion of the next annual general meeting of the Company or such earlier period, at the Annual General Meeting |

| | |
|---|---|
| "Latest Practicable Date" | 16 October 2025, being the latest practicable date prior to the printing of this circular for ascertaining certain information referred to in this circular |
| "Listing Rules" | the Rules Governing the Listing of Securities on the Stock Exchange |
| "Ms. Hai" | Ms. Hai Hiu Chu, the chairman of the Board, an executive Director, the chief executive officer and a controlling shareholder of the Company as at the Latest Practicable Date |
| "Nomination Committee" | the nomination committee of the Company |
| "Remuneration Committee" | the remuneration committee of the Company |
| "SFO" | Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time |
| "Share(s)" | ordinary share(s) with a nominal value of HK$0.01 each in the share capital of the Company |
| "Share Option Scheme" | the share option scheme conditionally approved and adopted by the Company pursuant to an ordinary resolution passed by its then shareholders on 24 June 2014 and became unconditional on 8 July 2014 |
| "Shareholder(s)" | holder(s) of Share(s) |
| "Stock Exchange" | The Stock Exchange of Hong Kong Limited |
| "Takeovers Code" | the Codes on Takeovers and Mergers and Share Buy-backs published by the Securities and Futures Commission of Hong Kong as amended, supplemented or otherwise modified from time to time |
| "treasury shares" | has the meaning as ascribed to it under the Listing Rules |
| "%" | per cent. |

# BAMBOOS HEALTH CARE HOLDINGS LIMITED
# 百本醫護控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2293)**

*Executive Directors:*
Ms. Hai Hiu Chu
*(Chairman and Chief Executive Officer)*
Mr. Cheng Sau Kong

*Independent non-executive Directors:*
Dr. Chan Kai Yue Jason
Mr. Wong Kon Man Jason
Mr. Tang Yi Hoi

*Registered office:*
PO Box 309, Ugland House
Grand Cayman
KY1-1104 Cayman Islands

*Head office and principal place of business in Hong Kong:*
Unit 901, 9/F, Good Hope Building
No. 612–618 Nathan Road
Mong Kok
Kowloon, Hong Kong

24 October 2025

*To the Shareholders,*

Dear Sir/Madam,

## PROPOSALS FOR
## (1) GENERAL MANDATES TO ISSUE AND BUY-BACK SHARES;
## (2) RE-ELECTION OF RETIRING DIRECTORS;
## (3) RE-APPOINTMENT OF AUDITOR;
## (4) DECLARATION OF A FINAL DIVIDEND;
## AND
## (5) NOTICE OF THE ANNUAL GENERAL MEETING

### INTRODUCTION

The purpose of this circular is to provide you with information in connection with the resolutions to be proposed at the Annual General Meeting relating to, inter alia, (i) the granting of the Issue Mandate, the Buy-back Mandate and the Extension Mandate; (ii) the re-election of the retiring Directors; (iii) the re-appointment of auditor; (iv) the declaration of a final dividend; and (v) the notice of the Annual General Meeting at which the above resolutions will be proposed to be considered and, if thought fit, approved.

## ISSUE MANDATE, BUY-BACK MANDATE AND EXTENSION MANDATE

Pursuant to the ordinary resolutions passed by the then Shareholders at the annual general meeting of the Company held on 28 November 2024, the Directors were granted mandates to issue new Shares and to buy back existing Shares. As at the Latest Practicable Date, those mandates to issue new Shares and to buy back existing Shares had not been utilized. Unless otherwise renewed, such general mandates will lapse at the conclusion of the Annual General Meeting.

At the Annual General Meeting, the following ordinary resolutions, among other matters, will be proposed:

(a) to grant to the Directors the Issue Mandate to allot, issue or otherwise deal with (including but not limited to the resale of treasury shares) further Shares representing up to 20% of the aggregate number of Shares in issue as at the date of passing of the relevant resolution;

(b) to grant the Buy-back Mandate to the Directors to enable them to buy-back Shares on the Stock Exchange up to a maximum of 10% of the aggregate number of Shares in issue as at the date of passing of such resolution; and

(c) to grant the Extension Mandate to the Directors to increase the total number of Shares which may be allotted and issued under the Issue Mandate (referred to in (a) above) by an additional number representing such number of Shares actually bought back under the Buy-back Mandate (referred to in (b) above).

As at the Latest Practicable Date, the issued Shares comprised 402,460,000 Shares. Assuming that there is no variation to the issued Shares during the period from the Latest Practicable Date to the date of passing of the resolution approving the Issue Mandate, the maximum number of Shares which may be issued pursuant to the Issue Mandate would be 80,492,000 Shares, not taking into account any additional new Shares which may be issued pursuant to the Extension Mandate. Such number of Shares referred to above shall, where applicable, be adjusted in the event that the Shares in issue as at the date of passing the resolutions are, at any time thereafter, converted into a larger or smaller number of Shares.

Each of the Issue Mandate, the Buy-back Mandate and the Extension Mandate will expire at the earliest of: (i) the conclusion of the next annual general meeting of the Company following the Annual General Meeting; (ii) the date by which the next annual general meeting is required by the Companies Act or the Articles of Association to be held; and (iii) when the authority given to the Directors thereunder is revoked or varied by ordinary resolution(s) of the Shareholders in a general meeting of the Company.

The Directors wish to state that they have no immediate plan to allot and issue any new Shares other than such Shares which may fall to be allotted and issued upon the exercise of the options granted under the Share Option Scheme of the Company.

The Board notes that with effect from 11 June 2024, the Listing Rules was amended to introduce flexibility for listed companies to cancel shares bought back and/or to adopt a framework to (i) allow shares bought back to be held in treasury; and (ii) govern the resale of treasury shares. Following such changes to the Listing Rules, if the Company buys back Shares pursuant to the Buy-back Mandate, the Company may cancel the Shares bought back and/or hold them as treasury shares, subject to market conditions and the Group's capital management needs at the relevant time of the Share buy-back. If the Company holds Shares in treasury, any resale of Shares held in treasury will be subject to the ordinary resolution numbered 8 of the AGM Notice and made in accordance with the Listing Rules and applicable laws and regulations of the Cayman Islands.

Under the Listing Rules, the Company is required to provide the Shareholders with all information reasonably necessary to enable the Shareholders to make an informed decision as to whether to vote for or against the ordinary resolution in respect of the Buy-back Mandate at the Annual General Meeting. An explanatory statement for such purpose is set out in **Appendix I** to this circular.

## RE-ELECTION OF RETIRING DIRECTORS

### Composition of the Board

As at the Latest Practicable Date, the Board consisted of five (5) Directors, namely:

| **Executive Directors** | **Date of appointment** |
|---|---|
| Ms. Hai Hiu Chu<br>*(Chairman and Chief Executive Officer)* | 23 November 2012 |
| Mr. Cheng Sau Kong | 1 December 2024 |
| **Independent non-executive Directors** | **Date of appointment** |
| Dr. Chan Kai Yue Jason | 1 April 2019 |
| Mr. Wong Kon Man Jason | 9 January 2019 |
| Mr. Tang Yi Hoi | 1 August 2025 |

### Directors proposed to be re-elected

According to Article 16.18 of the Articles of Association, at every annual general meeting of the Company, one-third of the Directors for the time being (or, if their number is not three or a multiple of three, then the number nearest to, but not less than, one-third) shall retire from office by rotation provided that every Director (including those appointed for a specific term) shall be subject to retirement by rotation at least once every three years.

Further, according to Article 16.2 of the Articles of Association, any Director appointed to fill a casual vacancy on the Board should hold office only until the first annual general meeting of the Company after his appointment and be subject to re-election at that meeting.

By virtue of Articles 16.2 and 16.18 of the Articles of Association, Mr. Tang Yi Hoi, Mr. Cheng Sau Kong, and Mr. Wong Kon Man Jason shall retire from office as Directors at the Annual General Meeting and will, being eligible, offer themselves for re-election.

On 26 September 2025, the Nomination Committee, having reviewed the Board composition, nominated each of the retiring Directors to the Board for recommendation to the Shareholders for re-election at the Annual General Meeting.

The nominations were made in accordance with the nomination policy of the Company and the selection criteria (including without limitation, gender, age, cultural and educational background, skills, knowledge and, professional experience), with due regard to the benefits of diversity, as set out under the Company's board diversity policy, as well as the respective contributions of the retiring Directors to the Board. Accordingly, with the recommendation of the Nomination Committee, the Board proposed that all the retiring Directors to stand for re-election at the Annual General Meeting. Each of the retiring Directors abstained from voting at the Board meeting regarding their respective propositions for re-election by the Shareholders at the Annual General Meeting.

The biographical information on each of the Directors who are proposed to be re-elected at the Annual General Meeting are set out in **Appendix II** to this circular.

## RE-APPOINTMENT OF THE AUDITOR

HLB Hodgson Impey Cheng Limited will retire as the auditor of the Company at the Annual General Meeting and, being eligible, offer themselves for re-appointment.

Upon the recommendation of the Audit Committee, the Board proposed to re-appoint HLB Hodgson Impey Cheng Limited as the auditor of the Company and to hold office until the conclusion of the next annual general meeting of the Company.

## DECLARATION OF A FINAL DIVIDEND

The Board has recommended the payment of a final dividend of HK1.50 cents per ordinary Share for the year ended 30 June 2025, subject to the approval of the Shareholders at the Annual General Meeting. The final dividend, if approved by the Shareholders at the Annual General Meeting, will be payable on Thursday, 18 December 2025 to Shareholders whose names appeared on the register of members of the Company on Friday, 5 December 2025. For details on closure of the register of members of the Company for entitlement to the final dividend, please refer to the paragraph headed "Closure of Register of Members" below.

## ANNUAL GENERAL MEETING

The AGM Notice at which ordinary resolutions will be proposed to approve, *inter alia*, (i) the grants of the Issue Mandate, the Buy-back Mandate and the Extension Mandate; (ii) the re-election of Directors; (iii) the re-appointment of auditor of the Company; and (iv) the declaration of a final dividend are set out on pages AGM-1 to AGM-6 of this circular.

A proxy form for use by the Shareholders at the Annual General Meeting is enclosed with this circular. Irrespective of whether you are able to attend and vote at the Annual General Meeting in person, you are requested to complete the enclosed proxy form in accordance with the instructions printed thereon and return it to the Branch Share Registrar, Union Registrars Limited, at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the Annual General Meeting or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude you from subsequently attending and voting at the Annual General Meeting or any adjournment thereof (as the case may be) should you so desire and in such event, the proxy form shall be deemed to be revoked.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder is required to abstain from voting on the resolutions to be proposed at the Annual General Meeting.

## VOTING BY POLL

In accordance with Rule 13.39(4) of the Listing Rules and the Articles of Association, the voting at the Annual General Meeting will be taken by poll. The Articles of Association also provides that on a poll, every Shareholder present in person or by proxy shall have one vote for every fully paid Share held by that Shareholder.

After the conclusion of the Annual General Meeting, an announcement on the poll results will be made available on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.bamboos.com.hk).

## CLOSURE OF REGISTER OF MEMBERS

### Entitlement to attend and vote at the Annual General Meeting

In order to determine the entitlement to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Friday, 21 November 2025 to Friday, 28 November 2025 (both days inclusive) during which period no transfer of Shares will be registered. All completed transfer form(s) accompanied by the relevant share certificate(s) must be lodged for registration with the Branch Share Registrar at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong by no later than 4:00 p.m. on Thursday, 20 November 2025.

**Entitlement to the recommended final dividend for the year ended 30 June 2025**

The record date for determination of entitlement of Shareholders to the recommended final dividend for the year ended 30 June 2025 is Friday, 5 December 2025.

For the purpose of ascertaining Shareholders' entitlement to the recommended final dividend, the register of members of the Company will be closed from Friday, 5 December 2025 to Monday, 8 December 2025 (both days inclusive) during which period no transfer of Shares may be effected. In order to qualify for the final dividend, all completed transfer form(s) accompanied by the relevant share certificate(s) must be lodged for registration with the Branch Share Registrar at the above address by no later than 4:00 p.m. on Thursday, 4 December 2025.

## RECOMMENDATIONS

The Board considers that (i) the proposed granting of the Issue Mandate, the Buy-back Mandate and the Extension Mandate; (ii) the proposed re-election of the retiring Directors as set out in Appendix II to this circular; (iii) the re-appointment of auditor; and (iv) the declaration of a final dividend are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

## RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

## GENERAL

Your attention is drawn to the additional information set out in the Appendices to this circular.

The translation into Chinese language of this circular is for reference only. In case of any inconsistency, the English version shall prevail.

Yours faithfully
By order of the Board
**Bamboos Health Care Holdings Limited**
**Hai Hiu Chu**
*Chairman*

*This appendix serves as an explanatory statement, as required under the Listing Rules, to provide the Shareholders with all the information reasonably necessary to enable them to make an informed decision on whether to vote for or against the ordinary resolution to approve the grant of the Buy-back Mandate to the Directors.*

## 1. LISTING RULES RELATING TO THE BUY-BACK MANDATE

The Listing Rules permit companies with a primary listing on the Stock Exchange to buy back their shares on the Stock Exchange subject to certain restrictions.

The Listing Rules provide that all proposed share buy-backs by a company with a primary listing on the Stock Exchange must be approved in advance by an ordinary resolution, either by way of a general mandate or by specific approval of a particular transaction. Such authority may only continue in force during the period from the passing of the resolution until the earliest of: (i) the conclusion of the next annual general meeting of the company; (ii) the expiry of the period within which the next annual general meeting of the company is required by law to be held; and (iii) the passing of an ordinary resolution by shareholders in general meeting of the company revoking or varying such mandate.

## 2. SHARE CAPITAL

As at the Latest Practicable Date, there were a total of 402,460,000 Shares in issue.

Subject to the passing of the relevant resolution granting to the Directors the Buy-back Mandate and on the basis that no new Shares are issued and no Shares are bought back for the period from the Latest Practicable Date up to and including the date of the Annual General Meeting, the Directors would be authorised under the Buy-back Mandate to buy back up to 40,246,000 Shares, representing a maximum of 10% of the aggregate number of Shares in issue of the Company as at the Latest Practicable Date.

## 3. STATUS OF SHARES BOUGHT BACK

As stated in the Letter from the Board in this circular, with effect from 11 June 2024, the Listing Rules was amended to introduce flexibility for listed companies to cancel shares bought back and/or to adopt a framework to (i) allow shares bought back to be held in treasury; and (ii) govern the resale of treasury shares.

Following such changes to the Listing Rules, if the Company buys back Shares pursuant to the Buy-back Mandate, the Company may cancel such Shares bought back and/or hold them as treasury shares, subject to market conditions and the Group's capital management needs at the relevant time of the Share buy-back. If the Company holds Shares in treasury, any resale of Shares held in treasury will be subject to the ordinary resolution numbered 8 of the AGM Notice and made in accordance with the Listing Rules and applicable laws and regulations of the Cayman Islands.

For any treasury shares deposited with CCASS pending resale on the Stock Exchange, the Company shall (i) procure its broker not to give any instructions to HKSCC to vote at general meetings of the Company for the treasury shares deposited with CCASS; and (ii) in the case of dividends or distributions, withdraw the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the record date for the dividends or distributions, or take any other measures to ensure that it will not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury shares.

## 4. REASONS FOR THE BUY-BACKS

Although the Directors have no present intention of exercising the proposed Buy-back Mandate, the Directors believe that the flexibility afforded by the proposed Buy-back Mandate is in the best interests of the Company and the Shareholders as a whole. An exercise of the Buy-back Mandate may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such buy-backs will benefit the Company and the Shareholders as a whole.

## 5. SOURCE OF FUNDS AND EFFECT OF BUY-BACKS

In making buy-backs, the Company may only apply funds legally available for such purpose in accordance with the Listing Rules, the Articles of Association, the Companies Act and all other applicable laws, rules and regulations, as the case may be.

Under the Listing Rules, a listed company may not buy back its own shares listed on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange as amended from time to time.

The laws of the Cayman Islands provide that the amount of capital repaid in connection with a share buy-back may only be paid out of either the capital paid up on the relevant shares, or the funds of the Company that would otherwise be available for dividend or distribution or the proceeds of a fresh issue of shares made for the purpose. The premium payable on buy-back may only be paid out of either the funds of the Company that would otherwise be available for dividend or distribution or out of the Company's share premium before the Shares are bought back. In accordance with the laws of the Cayman Islands, the Shares so bought back would be treated as cancelled but the aggregate amount of authorised share capital would not be reduced.

Taking into account the current working capital position of the Group, the Directors consider that, if the Buy-back Mandate were to be carried out in full at any time during the proposed buy-back period, it might have a material adverse impact on the working capital and/or gearing position of the Company as compared with the position as at 30 June 2025, being the date on which its latest published audited consolidated financial statements were made up. However, the Directors do not intend to exercise the Buy-back Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements or the

gearing position of the Company which in the opinion of the Directors are from time to time appropriate for the Company.

## 6. SHARE PRICES

The highest and lowest prices at which the Shares have been traded on the Stock Exchange in each of the twelve calendar months immediately preceding (and including) the Latest Practicable Date were as follows:

| | **Highest** | **Lowest** |
|---|---|---|
| | *HK$* | *HK$* |
| **2024** | | |
| October | 0.68 | 0.62 |
| November | 0.70 | 0.63 |
| December | 0.72 | 0.63 |
| **2025** | | |
| January | 0.75 | 0.66 |
| February | 0.72 | 0.63 |
| March | 0.67 | 0.55 |
| April | 0.62 | 0.50 |
| May | 0.59 | 0.50 |
| June | 0.54 | 0.49 |
| July | 0.58 | 0.49 |
| August | 0.59 | 0.55 |
| September | 0.58 | 0.49 |
| October (up to the Latest Practicable Date) | 0.55 | 0.50 |

## 7. DIRECTORS, THEIR CLOSE ASSOCIATES AND CORE CONNECTED PERSONS

As at the Latest Practicable Date, none of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their respective close associates, presently intend to sell any Shares to the Company or its subsidiaries under the Buy-back Mandate in the event that the grant of the Buy-back Mandate is approved by the Shareholders at the Annual General Meeting.

As at the Latest Practicable Date, no core connected persons of the Company have notified the Company that they have a present intention to sell any Shares, or have undertaken not to do so, to the Company in the event that the grant of the Buy-back Mandate is approved by the Shareholders at the Annual General Meeting.

## 8. THE TAKEOVERS CODE AND MINIMUM PUBLIC HOLDING

If a Shareholder's proportionate interest in the voting rights of the Company increases on the Company exercising its powers to buy-back securities pursuant to the Buy-back Mandate, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert (as defined in the Takeovers Code) could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, the register of the Shareholders maintained by the Company pursuant to Section 336 under Part XV of the SFO showed that the Company has been notified of the following interests, being 5% or more of the Company's issued share capital:

| **Name** | **Capacity** | **Number of Shares held (L)** *(Note 1)* | **Approximate % of the issued share capital of the Company** *(Note 4)* | **Approximate % of shareholding should the Buy-back Mandate be exercised in full** *(Note 5)* |
|---|---|---|---|---|
| Gold Empress | Beneficial owner *(Note 2)* | 270,864,000 | 67.30% | 74.78% |
| Ms. Hai | Interest of controlled corporation *(Note 2)* | 270,864,000 | 67.30% | 74.78% |
| HRnetGroup Limited *(Note 3)* | Beneficial owner | 32,000,000 | 7.95% | 8.83% |

*Notes:*

(1) The letter "L" denotes a long position in the shareholder's interest in the issued share capital of the Company.

(2) These 270,864,000 Shares are registered in the name of Gold Empress, the entire issued share capital of which is solely and beneficially owned by Ms. Hai. Ms. Hai is deemed to be interested in these 270,864,000 Shares held by Gold Empress by virtue of Part XV of the SFO. Both Gold Empress and Ms. Hai are regarded as controlling shareholders of the Company.

(3) HRnetGroup Limited is a corporation incorporated in Singapore whose issued shares are listed on the Main Board of the Singapore Exchange Securities Trading Limited.

(4) The percentage of shareholding is calculated on the basis of 402,460,000 Shares in issue as at the Latest Practicable Date.

(5) The percentage of shareholding is calculated on the basis of 362,214,000 Shares (on the basis of 402,460,000 Shares in issue as at the Latest Practicable Date and assuming the Buy-back Mandate was exercised in full).

Based on such interests, in the event that the Directors exercised in full the power to buy back Shares under the Buy-back Mandate which is proposed to be granted at the Annual General Meeting, the interests in the aggregate number of Shares in issue of the above controlling shareholders of the Company would be increased from approximately 67.30% to 74.78%. The Directors are not aware of any consequences which would give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code as a result of any Share buy-back to be made under the Buy-Back Mandate.

The Directors do not propose to exercise the Buy-back Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the aggregate number of Shares held by the public falling below 25% of the total number of the Shares in issue (or such other percentage as may be prescribed as the minimum public shareholding under the Listing Rules).

## 9. SHARES BOUGHT BACK BY THE COMPANY

The Company had not bought back any of the Shares (whether on the Stock Exchange or otherwise) within the six months immediately preceding the Latest Practicable Date.

## 10. GENERAL

The Directors will exercise the power of the Company to make buy-backs under the Buy-back Mandate (if so approved at the Annual General Meeting) in accordance with the Listing Rules, the Articles of Association and the applicable laws of the Cayman Islands.

The Directors have confirmed that neither this explanatory statement nor the Buy-back Mandate has any unusual features.

*Set out below are the biographical and other details of the Directors who, being eligible, will offer themselves for re-election at the Annual General Meeting.*

## EXECUTIVE DIRECTOR

### Mr. Cheng Sau Kong (鄭守崗) ("Mr. Cheng")

Mr. Cheng, aged 47, joined the Group in 2023 and has since been serving as a director of three wholly-owned subsidiaries of the Company, namely Bamboos Professional Nursing Services Limited, Bamboos Medical Centre Limited and Garden Medical Centre Limited, for which he is responsible for strategic development. Mr. Cheng has been appointed as an executive Director with effect from 1 December 2024.

Prior to joining the Group, Mr. Cheng worked at the public sector for more than 20 years. He worked in the Hong Kong Jockey Club as a Senior Manager, Charities during September 2022 to July 2023 and before such, he was Political Assistant to the Secretary for Food and Health from November 2017 to June 2022. Mr. Cheng also served at the Hospital Authority Head Office from 2007 to 2017. He is a Registered Nurse by profession. He graduated from The University of Hong Kong with a Bachelor's degree of Nursing and a Master's degree of Public Health (Health Economics and Policy).

Mr. Cheng has entered into a service agreement with the Company in relation to his appointment as an executive Director for an initial term of three (3) years commencing from 1 December 2024 and automatically renewable for fixed periods of three years thereafter, unless terminated by either party by giving not less than three (3) months' notice in writing. He is subject to retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. Pursuant to the service agreement, Mr. Cheng is entitled to a director's remuneration comprising (i) a monthly salary of HK$140,000; (ii) a guaranteed annual bonus equivalent to one additional month's salary; and (iii) a discretionary bonus to be determined from time to time by the Board and the Remuneration Committee. The director's remuneration for Mr. Cheng was determined by the Board based on the recommendation of the Remuneration Committee with reference to, among others, his experience and competence, involvement with the Group's affairs and the prevailing market condition. The amount of emoluments paid to Mr. Cheng for the year ended 30 June 2025 is set out in note 12 to the consolidated financial statements in the Company's annual report for the year ended 30 June 2025. As at the Latest Practicable Date, Mr. Cheng did not have any interests in the Shares or underlying Shares within the meaning of Part XV of the SFO.

Save as disclosed above and as far as the Directors are aware, Mr. Cheng (i) did not hold any other directorship in listed public companies in the last three years; (ii) did not hold any other positions with the Company or its subsidiaries; (iii) did not hold any other major appointments or professional qualifications; and (iv) was not connected and had no other relationship with any Directors, senior management or substantial or controlling shareholders of the Company as at the Latest Practicable Date.

Save as disclosed above, there are no other matters that need to be brought to the attention of the Shareholders nor other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules in relation to Mr. Cheng's re-election.

**INDEPENDENT NON-EXECUTIVE DIRECTOR**

**Mr. Tang Yi Hoi (鄧以海) ("Mr. Tang")**

Mr. Tang, JP, aged 60, has been an independent non-executive Director since 1 August 2025. He also serves as a member of each of the Audit Committee and the Nomination Committee and the chairman of the Remuneration Committee.

Mr. Tang joined the Immigration Department of Hong Kong in 1985, and subsequently joined the Customs and Excise Department of Hong Kong in 1987. He served as the Commissioner of Customs and Excise of Hong Kong in July 2017 and retired in October 2021. Mr. Tang was appointed as Justice of the Peace in October 2022. He has been awarded seven Assistant Commissioner of Customs and Excise's Commendations between 1992 and 2006; Commissioner of Customs and Excise's Commendation in 1997; Hong Kong Customs and Excise Long Service Medal in 2005, with the first and second clasps in 2012 and 2017 respectively; Hong Kong Customs and Excise Medal for Meritorious Service in 2014; Hong Kong Customs and Excise Medal for Distinguished Service in 2019; and the Silver Bauhinia Star in 2021.

Mr. Tang has been serving as a non-executive director and the vice-chairman of the board of directors of Vobile Group Limited (which is listed on the main board of the Stock Exchange, Stock Code: 3738) since July 2023, and has been appointed as an independent non-executive director of Chu Kong Shipping Enterprises (Group) Company Limited (which is listed on the main board of the Stock Exchange, Stock Code: 00560) and China Resources Building Materials Technology Holdings Limited (which is listed on the main board of the Stock Exchange, Stock Code: 1313) respectively since October 2024. He has also been appointed as independent non-executive director of JD Logistics Inc. (which is listed on the main board of the Stock Exchange, Stock Code: 2618) on 14 August 2025. He is currently a member of the Public Complaints Committee of the Hospital Authority of Hong Kong, a member of the Court of the Hong Kong Metropolitan University, and a director of Logistics and Supply Chain MultiTech R&D Centre Limited.

Mr. Tang holds a Bachelor of Arts degree in the Hong Kong Polytechnic University. He has completed the Advanced Management Programme at INSEAD (the Institut Européen d'Administration des Affaires) in France and the Advanced Management Programme at the National Academy of Governance in China.

Mr. Tang has entered into a letter of appointment with the Company for a fixed term of two years commencing from 1 August 2025 and renewable automatically for successive terms of one year each thereafter, subject to retirement from office and re-election at the next general meeting of the Company in accordance with the articles of association of the Company. Mr. Tang will receive a director's fee of HK$180,000 per annum, which is determined by the Board upon recommendation from the Remuneration Committee with reference to his qualifications, experiences, duties and responsibilities as an independent non-executive Director of the Company and prevailing market conditions.

Based on the information contained in the annual confirmation on independence provided by Mr. Tang to the Company pursuant to Rule 3.13 of the Listing Rules, the Board has reviewed and evaluated the independence of Mr. Tang and is satisfied that he has met the criteria of independence expected of an independent non-executive director under the Listing Rules. The Board is of the view that Mr. Tang remains independent, and has the character, integrity, independence and experience required to fulfil and discharge the role and duties of an independent non-executive Director in the event that he is re-elected at the Annual General Meeting.

Save as disclosed above and as far as the Directors are aware, Mr. Tang (i) did not hold any other directorship in listed public companies in the last three years; (ii) did not hold any other positions with the Company or its subsidiaries; (iii) did not hold any other major appointments or professional qualifications; (iv) was not connected and had no other relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (v) did not have any interests in the Shares or underlying Shares within the meaning of Part XV of the SFO as at the Latest Practicable Date.

Save as disclosed above, there are no other matters that need to be brought to the attention of the Shareholders nor other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules in relation to Mr. Tang's re-election.

**Mr. Wong Kon Man Jason (王幹文) ("Mr. Wong")**

Mr. Wong, aged 61, is an independent non-executive Director since January 2019 and the chairman of the Audit Committee and a member of the Remuneration Committee. Mr. Wong graduated from the University of Hawaii at Manoa in the United States with a bachelor's degree in business administration (majoring in accountancy) in 1988. He has over 26 years of experience in finance and investment. He was a financial consultant for Transpac Capital Ltd. from 1993 to 2000. He has been the managing director of Fortune Capital Group Limited since 2000. He is also one of the founding members and an investment committee member of Whiz Partners Asia Ltd. Since 2020, he is the chairman of Norwich Capital Limited. He is a member of American Institute of Certified Public Accountants and Hong Kong Institute of Certified Public Accountants.

Mr. Wong is currently serving as the chairman of the board and a non-executive director of Culturecom Holdings Limited (stock code: 343), the issued shares of which are listed on the Stock Exchange. Mr. Wong was an independent non-executive director of Shinsun Holdings (Group) Co., Ltd. (stock code: 2599) from 2020 to 2022, the issued shares of which are listed on the Stock Exchange; an independent non-executive director of Ascent International Holdings Limited (currently known as China International Development Corporation Limited) (stock code: 264) from 2017 to 2018, the issued shares of which are listed on the Stock Exchange; an independent non-executive director of China Lending Corporation Ltd. (Nasdaq: CLDC) from 2016 to 2017, the issued shares of which are listed on Nasdaq; an independent non-executive director of DT Asia Investments Ltd., from 2014 to 2016, the issued shares of which were previously listed on Nasdaq; an independent non-executive director of Group Sense (International) Limited (currently known as Rare Earth Magnesium Technology Group Holdings Limited) (stock code: 601) from 2004 to 2015, the issued shares of which is listed on the Stock Exchange; an independent non-executive director of Neo-Neon Holdings Limited (stock code: 1868) from 2011 to 2014, the issued shares of which are listed on the Stock Exchange; and an independent non-executive director of Polyard Petroleum International Group Limited (stock code: 8011) from 2010 to 2013.

Mr. Wong's appointment as an independent non-executive Director is for a fixed term of two years from 9 January 2019 which is renewable automatically for successive terms of one year upon expiry of the then current term of his appointment unless it is otherwise terminated earlier in accordance with his terms of appointment. His office as an independent non-executive Director is subject to retirement by rotation and re-election in accordance with the provisions of the Articles of Association. Mr. Wong was entitled to receive a director's fee of HK$15,000 per month. The director's fee of Mr. Wong was determined and will be reviewed by the Board annually with reference to his qualifications, experience, duties and responsibilities with the Company, as well as the Company's performance and the prevailing market conditions. For the financial year ended 30 June 2025, Mr. Wong received by way of remuneration the amount of HK$180,000 from the Company.

Based on the information contained in the annual confirmation on independence provided by Mr. Wong to the Company pursuant to Rule 3.13 of the Listing Rules, the Board has reviewed and evaluated the independence of Mr. Wong and is satisfied that he has met the criteria of independence expected of an independent non-executive director under the Listing Rules. The Board is of the view that Mr. Wong remains independent, and has the character, integrity, independence and experience required to fulfil and discharge the role and duties of an independent non-executive Director in the event that he is re-elected at the Annual General Meeting.

Save as disclosed above and as far as the Directors are aware, Mr. Wong (i) did not hold any other directorship in listed public companies in the last three years; (ii) did not hold any other positions with the Company or its subsidiaries; (iii) did not hold any other major appointments or professional qualifications; (iv) was not connected and had no other relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (v) did not have any interests in the Shares or underlying Shares within the meaning of Part XV of the SFO as at the Latest Practicable Date.

Save as disclosed above, there are no other matters that need to be brought to the attention of the Shareholders nor other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules in relation to Mr. Wong's re-election.

# BAMBOOS HEALTH CARE HOLDINGS LIMITED
# 百本醫護控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2293)**

## NOTICE OF ANNUAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that the annual general meeting (the "**Meeting**") of Bamboos Health Care Holdings Limited (the "**Company**") will be held at Unit 801, 8/F, Good Hope Building, No. 612–618 Nathan Road, Mong Kok, Kowloon, Hong Kong on Friday, 28 November 2025 at 11:00 a.m. to consider and, if thought fit, transact the following:

### ORDINARY RESOLUTIONS

1. To receive and approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors (the "**Directors**", each a "**Director**") and of the auditor of the Company for the year ended 30 June 2025.

2. To re-elect Mr. Cheng Sau Kong as an executive Director.

3. To re-elect Mr. Tang Yi Hoi as an independent non-executive Director.

4. To re-elect Mr. Wong Kon Man Jason as an independent non-executive Director.

5. To authorise the board of Directors (the "**Board**") to fix the remuneration of the Directors.

6. To re-appoint HLB Hodgson Impey Cheng Limited as the auditor of the Company for the year ending 30 June 2026 and to authorise the Board to fix its remuneration.

7. To approve payment of a final dividend for the year ended 30 June 2025.

**As special business**

8. "**THAT:**

   (a) subject to paragraphs (c) and (d) below, and pursuant to the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), and all other applicable laws, the Directors be and are hereby granted an unconditional general mandate to allot,

issue and deal with additional shares in the capital of the Company (the "**Share(s)**"), including but not limited to the resale of treasury shares, and to allot, issue or grant securities convertible into Shares, options, warrants and other rights to subscribe for any Shares in the share capital of the Company or such convertible securities and to make or grant offers, agreements and options in respect thereof;

(b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period (as defined below) to make or grant offers, agreements and options (including warrants, bonds, notes and other securities which carry rights to subscribe for or are convertible into Shares) which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the aggregate number of the Shares allotted and issued or agreed conditionally or unconditionally to be allotted and issued (whether pursuant to an option or otherwise) by the Directors pursuant to the approval in paragraph (a) above of this resolution, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of any options granted under the share option scheme or similar arrangements for the time being adopted by the Company from time to time in accordance with the Listing Rules;

(iii) any scrip dividend or similar arrangements providing for the allotment and issue of Shares in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company and other relevant regulations in force from time to time; or

(iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any warrants of the Company or any securities which are convertible into Shares;

shall not exceed 20% of the aggregate number of Shares in issue as at the date of the passing of this resolution, and the said approval shall be limited accordingly;

(d) the Company may not issue securities convertible into new Shares for cash consideration unless the initial conversion price is not lower than the Benchmarked Price (as defined below) of the Shares at the time of the relevant placing, and the Company may not issue warrants, options or similar rights to subscribe for (i) any new Shares; or (ii) any securities convertible into new Shares, for cash consideration pursuant to the approval in paragraph (a) above; and

(e) for the purposes of this resolution,

"**Benchmarked Price**" means the higher of:

(i) the closing price on the date of the relevant placing agreement or other agreement involving the proposed issue of securities pursuant to the approval in paragraph (a) above; and

(ii) the average closing price in the 5 trading days immediately prior to the earlier of:

(1) the date of announcement of the placing or the proposed transaction or arrangement involving the proposed issue of securities pursuant to the approval in paragraph (a) above;

(2) the date of the placing agreement or other agreement involving the proposed issue of securities pursuant to the approval in paragraph (a) above; and

(3) the date on which the placing or subscription price is fixed.

"**Relevant Period**" means the period from the date of passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws of the Cayman Islands to be held; or

(iii) the date on which such mandate granted under this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

"**Rights Issue**" means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to the holders of Shares or any class of Shares whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such Shares as at that date (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expenses or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, jurisdiction outside Hong Kong or any recognised regulatory body or any stock exchange outside Hong Kong)."

9. "**THAT**:

(a) subject to paragraph (b) below of this resolution, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to buy back the Shares in the share capital of the Company listed on the Stock Exchange or any other stock exchange on which Shares may be listed and which is recognised by the Securities and Futures Commission of Hong Kong (the "**SFC**") and the Stock Exchange for such purpose, and subject to and in accordance with all applicable laws and the requirements of Listing Rules and the rules and regulations of the SFC in this regard, be and is hereby generally and unconditionally approved;

(b) the aggregate number of Shares which may be bought back or agreed to be bought back by the Company pursuant to the approval in paragraph (a) above during the Relevant Period shall not exceed 10% of the aggregate number of Shares in issue as at the date of the passing of this resolution, and the said approval shall be limited accordingly; and

(c) for the purpose of this resolution, "**Relevant Period**" means the period from the date of passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any other applicable laws of the Cayman Islands to be held; or

(iii) the date on which such mandate granted under this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting."

10. "**THAT** conditional upon resolutions numbered 8 and 9 above being passed, the unconditional general mandate granted to the Directors to allot, issue and deal with the unissued Shares in the Company pursuant to resolution numbered 8 above be and is hereby extended by the addition to the aggregate number of Shares which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to or in accordance with such general mandate of an amount representing the aggregate number of Shares bought back by the Company pursuant to or in accordance with the authority granted under resolution numbered 9 above."

Yours faithfully
By order of the Board
**Bamboos Health Care Holdings Limited**
**Hai Hiu Chu**
*Chairman*

Hong Kong, 24 October 2025

*Registered office:*
PO Box 309, Ugland House
Grand Cayman
KY1-1104
Cayman Islands

*Head office and principal place of business in Hong Kong:*
Unit 901, 9/F, Good Hope Building
No. 612–618 Nathan Road
Mong Kok
Kowloon, Hong Kong

*Notes:*

1. A member of the Company entitled to attend and vote at the Meeting is entitled to appoint another person as his proxy to attend and vote in his stead. A member who is the holder of two or more Shares may appoint more than one proxy to represent him and vote on his behalf at the Meeting. A proxy need not be a member of the Company.

2. In the case of joint holders of Shares, any one of such joint holders may vote, either in person or by proxy, in respect of such Shares as if he were solely entitled thereto, but if more than one of such joint holders are present at the Meeting, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.

3. In order to be valid, the form of proxy must be in writing under the hand of the appointor or of his attorney duly authorised in writing, or if the appointor is a corporation, either under seal, or under the hand of an officer or attorney duly authorised, and must be deposited with Union Registrars Limited, the Hong Kong branch share registrar and transfer office of the Company (the "**Branch Share Registrar**"), at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong (together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy thereof) not less than 48 hours before the time fixed for holding of the Meeting (or any adjournment thereof).

4. Delivery of an instrument appointing a proxy should not preclude a member from attending and voting in person at the Meeting or any adjournment thereof and in such event, the instrument appointing a proxy shall be deemed to be revoked.

5. In relation to resolutions numbered 8 and 10 above, approval is being sought from the members of the Company for the grant to the Directors of a general mandate to authorise the allotment and issue of Shares. The Directors have no immediate plans to issue any new Shares other than Shares which may fall to be issued upon exercise of the subscription rights attached to the options granted under the share option scheme of the Company or any scrip dividend scheme which may be approved by the members of the Company.

6. In relation to resolution numbered 9 above, the Directors wish to state that they will exercise the powers conferred thereby to buy-back Shares in circumstances, which they deem appropriate for the benefit of the members of the Company. An explanatory statement containing the information necessary to enable the members of the Company to make an informed decision to vote on the proposed resolution as required by the Listing Rules is set out in Appendix I to the circular of which this notice forms part.

7. In order to determine the qualification to attend and vote at the Meeting, the register of members of the Company will be closed from Friday, 21 November 2025 to Friday, 28 November 2025 (both days inclusive) during which period no transfer of Shares will be registered. All completed transfer form(s) accompanied by the relevant share certificate(s) must be lodged for registration with the Branch Share Registrar at the above address by no later than 4:00 p.m. on Thursday, 20 November 2025.

8. The record date for determination of the entitlement of members of the Company to the recommended final dividend for the year ended 30 June 2025 is Friday, 5 December 2025. In order to determine the entitlement to the recommended final dividend, if approved by the Shareholders at the Meeting, the register of members of the Company will be closed from Friday, 5 December 2025 to Monday, 8 December 2025 (both days inclusive) during which period no transfer of Shares will be registered. All completed transfer form(s) accompanied by the relevant share certificate(s) must be lodged for registration with the Branch Share Registrar at the above address by no later than 4:00 p.m. on Thursday, 4 December 2025.

9. If a Typhoon Signal No. 8 or above is hoisted or a Black Rainstorm Warning Signal or "extreme conditions after super typhoons" as announced by the Hong Kong Government is/are in force at any time after 9:00 a.m. on the date of the Meeting, the Meeting will be postponed. The Company will post an announcement on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.bamboos.com.hk) to notify its shareholders of the date, time and place of the re-scheduled meeting.

*As at the date of this notice, the executive Directors are Ms. Hai Hiu Chu (Chairman and Chief Executive Officer) and Mr. Cheng Sau Kong; and the independent non-executive Directors are Dr. Chan Kai Yue Jason, Mr. Wong Kon Man Jason and Mr. Tang Yi Hoi.*